AI-Designed Drugs Expected to Enter the Market by the End of the Decade
A pharmaceutical startup has announced that the first drugs fully designed using artificial intelligence (AI) could reach the market by the end of this decade.
Alex Zhavoronkov, CEO of Insilico Medicine, stated, “I would be surprised if this does not happen within the next 5 to 6 years; we hope to be the first company to achieve this milestone.”
While there is great optimism about AI’s potential to reduce the cost and time required for drug development, no AI-designed drug has yet been approved and brought to market. However, Takeda is in the final stages of testing an AI-designed drug for psoriasis, with data expected to be released later this year.
Artificial intelligence is transforming many industries by enabling faster and more efficient processes. In drug discovery, AI can analyze vast datasets, identify potential drug candidates, and optimize molecular structures much quicker than traditional methods. This technological advancement promises to revolutionize how new therapies are developed, potentially accelerating access to effective treatments for patients worldwide.
